Company news

Bavarian Nordic A/s (OMXCOP:BAVA) news

Every Bavarian Nordic A/s press release and news update in one place — announcements, filings coverage, and company updates for investors.

View Bavarian Nordic A/s stock analysis →

Press releases & updates

Bavarian Nordic Reports Strong First Half 2026 Results

August 21, 2026

Bavarian Nordic to Launch New Share Buy-back Program of up to DKK 750 Million

August 21, 2026

Bavarian Nordic Upgrades its Full-Year 2026 Financial Guidance

August 21, 2026

Bavarian Nordic’s Chikungunya Vaccine Submitted for Regulatory Approval in Brazil

July 13, 2026

Bavarian Nordic A/S : - Completion of Share Buy-Back Program

July 13, 2026

Bavarian Nordic Receives Health Canada Approval for Chikungunya Vaccine

June 29, 2026

Bavarian Nordic Secures Additional Government Contract for the Supply of Smallpox/Mpox Vaccine

June 9, 2026

Bavarian Nordic Announces Interim Results for the First Three Months of 2026

May 13, 2026

Bavarian Nordic Awarded Contract Options from the U.S. Government for Production and Supply of Freeze-dried Smallpox Vaccines

May 11, 2026

Resolutions of the Annual General Meeting 2026 of Bavarian Nordic A/S

April 21, 2026

Bavarian Nordic – Transactions in Connection with Share Buy-Back Program

April 20, 2026

Bavarian Nordic Receives Swissmedic Approval for Chikungunya Vaccine

April 16, 2026

Bavarian Nordic A/S : - Transactions in Connection with Share Buy-Back Program

April 13, 2026

Bavarian Nordic Submits Data to EMA to Extend Mpox and Smallpox Vaccine Approval to Children Aged 2-11 Years

March 27, 2026

Bavarian Nordic A/S – Notice Convening Annual General Meeting

March 24, 2026

Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/...

March 12, 2026

Bavarian Nordic Launches Next Tranche of Share Buy-Back Program

March 12, 2026

Bavarian Nordic Publishes Annual Report 2025

March 12, 2026

Bavarian Nordic and Serum Institute of India Expand Strategic Partnership with Chikungunya Vaccine Manufacturing Agreement

March 11, 2026

Paul Chaplin Steps Down as CEO of Bavarian Nordic

March 2, 2026

Bavarian Nordic Receives USD 22.5 Million Contract for its Mpox and Smallpox Vaccine from the Government of Canada

February 18, 2026

Bavarian Nordic Reports Preliminary 2025 Financial Results and Provides Guidance for 2026

February 12, 2026

Bavarian Nordic – Completion of Share Buy-Back Program

February 9, 2026

Bavarian Nordic Signs Distribution Agreement with Eurofarma to Expand Access to Chikungunya Vaccine in Brazil

January 23, 2026

Bavarian Nordic Launches Planned Share Buy-Back Program

January 7, 2026

Bavarian Nordic Establishes Long-term Incentive Program for Members of Executive Management and Selected Employees

December 18, 2025

Heidi Hunter Appointed New Vice Chair of the Board of Directors of Bavarian Nordic

December 17, 2025

Bavarian Nordic to Launch Share Buy-back Program of up to DKK 500 Million

December 2, 2025

Bavarian Nordic to Host a Shareholder Information Meeting on December 11, 2025 in Copenhagen

November 26, 2025

Bavarian Nordic Announces Interim Results for the First Nine Months of 2025

November 14, 2025

Bavarian Nordic Announces Changes to the Board of Directors

November 13, 2025

Bavarian Nordic Announces Major Shareholder Notification from Morgan Stanley

November 10, 2025

Consortium consisting of Nordic Capital and Permira announces preliminary result of the takeover offer to shareholders of Bavarian Nordic...

November 6, 2025

Bavarian Nordic Provides Clarification on the HERA Framework Agreement and the Public Preparedness Business

November 1, 2025

Bavarian Nordic shareholders are reminded of expiry of the offer period regarding the takeover offer from consortium consisting of Nordic...

October 31, 2025

Bavarian Nordic Awarded New Procurement Framework Contract by the European Commission to Strengthen Preparedness Against Smallpox and Mpox

October 31, 2025

Bavarian Nordic Provides Further Support to Mpox Outbreak in Africa through Additional Donation of Vaccines

October 28, 2025

Consortium consisting of Nordic Capital and Permira lowers the minimum acceptance condition to 66 2/3% in respect of the takeover offer t...

October 21, 2025

The Board of Directors maintains its recommendation in supplementary statement in respect of the improved takeover offer to the sharehold...

October 16, 2025

Consortium consisting of Nordic Capital and Permira increases offer price and extends offer period until 5 November 2025 in respect of th...

October 15, 2025

Consortium consisting of Nordic Capital and Permira receives final regulatory approval in respect of its takeover offer to the shareholde...

October 9, 2025

Bavarian Nordic Reports Positive Topline Data for Mpox/Smallpox Vaccine in Pediatric Population

October 7, 2025

Consortium consisting of Nordic Capital and Permira extends offer period until 14 October 2025 and provides update on regulatory approval...

September 29, 2025

Societe Generale: shares & voting rights as of 31 August 2025

September 9, 2025

Capital Increase in Bavarian Nordic A/S as a Result of Employee Warrant Exercise

September 5, 2025

Publication of statement by the Board of Directors in respect of the takeover offer to the shareholders of Bavarian Nordic from the conso...

August 26, 2025

Publication of offer document in respect of the takeover offer to the shareholders of Bavarian Nordic from the consortium led by Nordic C...

August 26, 2025

Bavarian Nordic Announces First Half 2025 Results

August 22, 2025

Bavarian Nordic Announces Closing of Sale of Priority Review Voucher and Upgrades its 2025 Financial Guidance

July 31, 2025

Consortium Led by Nordic Capital and Permira Will Make All-Cash Recommended Purchase Offer for Bavarian Nordic

July 28, 2025

Older →